Established assays such as Prosigna, Mammaprint, Oncotype DX, and EndoPredict provide valuable insights into tumour biology, recurrence risk, and likely response to endocrine or chemotherapy in ER+/HER2− early-stage breast cancer. Here, ESR1 is linked to neoplasm.